Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel DuPage

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Cell Reports|June 14, 2018
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer ImmunityDavid Wang, Jason Quiros, Kelly Mahuron, et al.
Immunity|September 6, 2015
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell ResponsesNikhil S Joshi, Elliot H Akama-Garren, Yisi Lu, et al.
Nature|October 25, 2019
MHC-II neoantigens shape tumour immunity and response to immunotherapyElise Alspach, Danielle M Lussier, Alexander P Miceli, et al.
Immunity|February 10, 2019
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint BlockadeChien-Chun Steven Pai, John T Huang, Xiaoqing Lu, et al.
Blood|February 28, 2022
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesMichael C Zaiken, Ryan Flynn, Katelyn G Paz, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Cell Reports|June 14, 2018
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer ImmunityDavid Wang, Jason Quiros, Kelly Mahuron, et al.
Immunity|September 6, 2015
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell ResponsesNikhil S Joshi, Elliot H Akama-Garren, Yisi Lu, et al.
Nature|October 25, 2019
MHC-II neoantigens shape tumour immunity and response to immunotherapyElise Alspach, Danielle M Lussier, Alexander P Miceli, et al.
Immunity|February 10, 2019
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint BlockadeChien-Chun Steven Pai, John T Huang, Xiaoqing Lu, et al.
Blood|February 28, 2022
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesMichael C Zaiken, Ryan Flynn, Katelyn G Paz, et al.
Pageof 4